The Role of Positron Emission Tomography–Computed Tomography in the Workup of Non–Small Cell Lung Cancer
Menée aux Etats-Unis à partir de données portant sur 64 103 patients atteints d'un cancer du poumon non à petites cellules diagnostiqué entre 2000 et 2013, cette étude évalue l'association entre l'utilisation de la tomographie numérique par émission de positrons avant et après le diagnostic de la maladie et la mortalité spécifique à 5 ans ainsi que la mortalité toutes causes confondues
Non–small cell lung cancer (NSCLC) remains a significant global health burden and is a leading cause of cancer-related death. The correct staging of patients with NSCLC is a key step in selecting an adequate treatment regimen, and combined positron emission tomography–computed tomography (PET-CT) with fluorine 18–labeled fluorodeoxyglucose (FDG) is increasingly used for staging and treatment monitoring of patients with NSCLC. The principal strengths of PET-CT with FDG in staging NSCLC include the assessment of intrathoracic lymph nodes and the detection of unanticipated stage IV disease. However, data on the effects of PET-CT with FDG on cancer-related mortality in NSCLC remain sparse.
JAMA Network Open , commentaire en libre accès, 2018